Page 88 - Read Online

Page 18 of 21 Toniutto et al. Hepatoma Res 2020;6:50 I http://dx.doi.org/10.20517/2394-5079.2020.40

41. Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver
transplantation. World J Hepatol 2019;11:50-64.
42. Pommergaard HC, Burcharth J, Rosenberg J, Rasmussen A. Serologic and molecular biomarkers for recurrence of hepatocellular
carcinoma after liver transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando) 2016;30:171-7.
43. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, et al. Liver transplantation for hepatocellular carcinoma: a model
including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-94 e3; quiz e14-5.
44. Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, et al. Validation of the AFP model as a predictor of HCC recurrence in
patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol 2017;66:552-9.
45. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver
transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:987-99.
46. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular
carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010;10:129-37.
47. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors
progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl
2013;19:1108-18.
48. Han K, Tzimas GN, Barkun JS, Metrakos P, Tchervenkov JL, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular
carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007;21:39-45.
49. Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, et al. Pretransplantation alpha-fetoprotein slope and milan criteria: strong
predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation 2013;95:228-33.
50. Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, et al. Specific issues concerning the management of patients on the
waiting list and after liver transplantation. Liver Int 2018;38:1338-62.
51. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, et al. Liver transplantation for advanced hepatocellular carcinoma using poor
tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011;253:166-72.
52. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, et al. The extended Toronto criteria for liver transplantation in patients
with hepatocellular carcinoma: a prospective validation study. Hepatology 2016;64:2077-88.
53. Zheng SS, Xu X, Wu J, Chen J, Wang WL, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.
Transplantation 2008;85:1726-32.
54. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular
carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009;49:832-8.
55. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, et al. Total tumor volume and alpha-fetoprotein for selection of
transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 2015;62:158-65.
56. Varona MA, Soriano A, Aguirre-Jaime A, Garrido S, Oton E, et al. Risk factors of hepatocellular carcinoma recurrence after liver
transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc 2015;47:84-9.
57. Pinero F, Tisi Bana M, de Ataide EC, Hoyos Duque S, Marciano S, et al. Liver transplantation for hepatocellular carcinoma: evaluation of
the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int 2016;36:1657-67.
58. Rhu J, Kim JM, Choi GS, Kwon CHD, Joh JW. Validation of the alpha-fetoprotein model for hepatocellular carcinoma recurrence after
transplantation in an Asian population. Transplantation 2018;102:1316-22.
59. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, et al. Metroticket 2.0 Model for analysis of competing risks of death after liver
transplantation for hepatocellular carcinoma. Gastroenterology 2018;154:128-39.
60. Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of
hepatocellular carcinoma. Cancer 1988;61:1621-8.
61. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, et al. The predictors of microvascular invasion in candidates for liver
transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg
Oncol 2007;95:235-40.
62. Pote N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and
prediction of microvascular invasion. J Hepatol 2015;62:848-54.
63. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, et al. Comparison of clinicopathological features of patients with hepatocellular
carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol
Hepatol 2001;16:1290-6.
64. Hong YM, Cho M, Yoon KT, Chu CW, Yang KH, et al. Risk factors of early recurrence after curative hepatectomy in hepatocellular
carcinoma. Tumour Biol 2017;39:1010428317720863.
65. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the
recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-7.
66. Takada Y, Ito T, Ueda M, Sakamoto S, Haga H, et al. Living donor liver transplantation for patients with HCC exceeding the Milan
criteria: a proposal of expanded criteria. Dig Dis 2007;25:299-302.
67. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor
liver transplantation for hepatocellular carcinoma. Am J Transplant 2009;9:2362-71.
68. Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation
for hepatocellular carcinoma. Surgery 2013;154:1053-60.
69. Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, et al. Extended indication for living donor liver transplantation in patients